Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07288333 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

Name: Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia — clinical trial record (NCT07288333)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorNeurocrine Biosciences

Started2026-02-16

View on ClinicalTrials.gov ↗

Amendment history

2026-07-21

Study Status, Contacts/Locations v4

Study sites5→6

2026-05-22

Study Status, Contacts/Locations v3

Trial sites expanded: 2 → 5 locations

2026-04-10

Study Status, Contacts/Locations v2

Recruitment opened

Start dateestimated 2026-03→confirmed 2026-02-16

Study sites0→2

2026-03-02

Study Status v1

Start date2025-12→2026-03

2025-12-15

Original filing

Neurocrine Biosciences

25 trials monitored

See 1 trial at risk

Schizophrenia

675 trials monitored

See 32 trials at risk

The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.

Trial Details

NCT Number	NCT07288333
Lead Sponsor	Neurocrine Biosciences
Conditions	Schizophrenia
Enrollment	120 participants
Start Date	2026-02-16
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-22